Observational cohort following people with Parkinson's disease and multiple system atrophy in Shanghai
Follows people with Parkinson's disease and multiple system atrophy over time through tests and samples.
Plain-language title generated from the registry record
Registry title: Shanghai Clinical Cohort - Parkinson's Disease (Reserve)
Key facts
- Where
- Shanghai, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people in Shanghai with Parkinson's disease or multiple system atrophy. They give samples, have scans and tests, and come for follow-up visits every 6 months.
- Sex
- All sexes can join.
- Disease stage
- A clinical diagnosis of Parkinson's disease (Chinese 2016 criteria) or clinically probable multiple system atrophy (Chinese 2022 criteria).
Main reasons for not taking part
- Unclear or uncertain diagnosis
- History of stroke, head trauma, hydrocephalus, brain tumor, or brain surgery
- Brain lesions seen on CT or MRI
- Severe anxiety, depression, or schizophrenia
- Severe heart, lung, liver, kidney, hormone, or blood disease
Read by machine on 13 November 2026.
Where in China
- Department of neurology, Ruijin Hospital, Shanghai Jiao Tong University School of MedicineShanghai, ChinaContact: Jun Liu, ProfessorTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Ruijin Hospital
- Trial code
- NCT07353463
- Record updated
- 5 March 2026
- Original description
The goal of this observational cohort studyis to establish a high-quality clinical cohort of Parkinson's disease (PD) and multiple system atrophy (MSA) patients in Shanghai, in order to improve early diagnosis, precise subtyping, disease monitoring, and to provide a resource for translational research and novel therapy development.Read full original descriptionShow less
Shanghai Clinical Cohort - Parkinson's Disease (Reserve)
The goal of this observational cohort studyis to establish a high-quality clinical cohort of Parkinson's disease (PD) and multiple system atrophy (MSA) patients in Shanghai, in order to improve early diagnosis, precise subtyping, disease monitoring, and to provide a resource for translational research and novel therapy development.
The main questions it aims to answer are:
* Can multimodal data (clinical, imaging, electrophysiology, biospecimens, and genetics) help identify early biomarkers for PD and MSA? * Can precise subtyping and long-term monitoring predict disease progression and therapeutic response? Researchers will compare 600 PD patients and 100 MSA patients to evaluate differences in clinical features, biomarkers, imaging, and prognosis.
Participants will:
* Provide informed consent and complete baseline demographic and medical history collection. * Undergo standardized clinical evaluations, including motor and non-motor symptom scales, cognitive and quality-of-life assessments. * Provide biological samples (blood, saliva, optional CSF). * Receive brain imaging (MRI, optional PET/SPECT) and electrophysiological recordings (EEG, fNIRS). * Participate in longitudinal follow-up visits every 6 months for repeat assessments.
This study will create a sustainable, multicenter, and sharable cohort platform to support early identification, personalized intervention, and therapeutic development for neurodegenerative diseases
Inclusion Criteria for Clinical PD Group:; Patients with a clinical diagnosis of Parkinson's disease (PD) according to the _Chinese Diagnostic Criteria for Parkinson's Disease (2016 edition)_; Willingness to undergo biospecimen collection, including cerebrospinal fluid (optional), blood, and saliva, and to complete neuroimaging examinations (MRI, PET/SPECT) and disease-specific clinical assessments; Provision of written informed consent; Inclusion Criteria for Clinical MSA Group:; Patients with a clinical diagnosis or clinically probable multiple system atrophy (MSA) according to the Chinese Expert Consensus on the Diagnostic Criteria for MSA (2022); Willingness to undergo biospecimen collection, including cerebrospinal fluid (optional), blood, and saliva, and to complete neuroimaging examinations (MRI, PET/SPECT) and disease-specific clinical assessments; Provision of written informed consent; Exclusion Criteria for All Participants:; Patients with an unclear or uncertain diagnosis; History of stroke, head trauma, hydrocephalus, brain tumor, intracranial hypertension, or intracranial surgery; Evidence of intracranial organic lesions on CT/MRI; Severe anxiety, depression, or schizophrenia; Severe comorbidities involving the heart, lungs, liver, kidneys, endocrine system, or hematological system; Presence of aphasia, severe dysarthria, or other conditions that significantly impair clinical assessments; Anticipated poor compliance.